Company news
Replicel Life Sciences Inc. (OTC:REPCF) news
Replicel Life Sciences Inc. news releases on 6ix. Latest, Aug 5, 2020: BCSC Revocation of Cease Trade Order
Press releases & updates
BCSC Revocation of Cease Trade Order
August 4, 2020
BCSC Cease Trade Order
June 16, 2020
RepliCel Announces its Incoming Board of Directors
December 23, 2019
RepliCel Provides 2019 Year-End Update
November 26, 2019
Clinical Data Published from RepliCel's Skin Rejuvenation Study
September 24, 2019
RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China
September 10, 2019
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector
August 29, 2019
RepliCel Secures Several New Patents for its Regenerative Medicine Technologies
April 16, 2019
RepliCel's Licensee Building Momentum in China with Facility and Team
March 26, 2019
RepliCel Reignites its First-in-Japan Strategy
March 19, 2019
RepliCel CEO Provides 2019 Shareholder Update
March 5, 2019
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
November 6, 2018
RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada
October 18, 2018
RepliCel Life Sciences Appoints New Chief Financial Officer
October 17, 2018
RepliCel CEO Provides Updated Outlook
October 15, 2018
RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
October 11, 2018
RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
September 24, 2018
RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
July 11, 2018
RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
May 2, 2018
RepliCel CEO Provides 2018 Shareholder Update
January 25, 2018
RepliCel Life Sciences Lands Commitment for Key Investment Partnership
January 16, 2018
RepliCel Life Sciences Successfully Closes Financing
October 19, 2017
Streetwise Reports Interviews CJ Partners' Colin Lee Novick Who Says Japan is Fertile Ground for Biotech Deals
October 6, 2017
RepliCel Retains Hybrid Financial for Investor Relations
September 21, 2017
RepliCel's Partnership Initiatives Mature into Licensing Negotiations
September 13, 2017
RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
September 7, 2017
Streetwise Reports Examines Analyst's View that Cell Therapy Company's Move Decreases Risk
August 24, 2017
RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program
August 16, 2017
Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data
August 10, 2017
RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map
June 13, 2017
RepliCel CEO Provides Company Outlook
May 25, 2017
United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
April 25, 2017
The Life Sciences Report Examines How Positive Trial Results Boost RepliCel's Profile
April 13, 2017
Positive Results from RepliCel's RCS-01 Phase I Skin Trial are the Company's Most Compelling to Date
April 4, 2017
RepliCel's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
March 28, 2017
The Life Sciences Report Examines RepliCel's Phase 1 Trial for Hair Loss Completed Successfully
March 17, 2017
RepliCel's Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints
March 14, 2017
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
March 7, 2017
RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
February 28, 2017
RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
February 9, 2017
RepliCel Life Sciences Inc. announces Brokered Private Placement
February 7, 2017
RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors
February 3, 2017
The Life Sciences Report Examines Companies Flocking to Japan for Biotech Deals
February 2, 2017
RepliCel CEO Provides 2017 Forecast
January 5, 2017
RepliCel Life Sciences Share Consolidation Approved
August 9, 2016
RepliCel Life Sciences Continues Restructuring With Share Structure Consolidation
July 22, 2016
RepliCel's Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
July 21, 2016
RepliCel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price
April 29, 2016
RepliCel Life Sciences Conducts Formal Consultation Review With Japan's PMDA and Receives Unprecedented Review Fee Reduction
April 25, 2016
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
April 20, 2016